Previous evidence suggests that once-weekly insulin dosing regimens are viewed positively by people with type 2 diabetes16; a study of injectable glucagon-like peptide 1 receptor agonists demonstrated that once-weekly treatments for type 2 diabetes may improve treatment adherence and persistence compared...
Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel class of injectable antidiabetic drugs. Previous studies indicated that GLP-1R... X Guo,...
have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are pregnant or plan to become pregnant. Wegovy ® may harm your unborn baby. You should stop using Wegovy ® 2 months before you plan to become pregnant a...
The once-daily human GLP-1 analog liraglutide reduces the prevalence of prediabetes and improves systolci blood pressure in obese non-diabetic subjects: a 52-week randomized placebo controlled trial N Finer,M Al Hakim,L Van Gaal,... - 《Finer N》 被引量: 2发表: 2009年 Safety, tolerabilit...
Investigational compounds also in the pipeline include the once-daily injectable GLP-1 agonist lixisenatide as monotherapy and in combination with basal insulin as well as long-acting insulin analogs. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and...